FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 03/10/2004 |
3. Issuer Name and Ticker or Trading Symbol
XCYTE THERAPIES INC [ XCYT ] |
|||||||||||||
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Beneficially Owned | |||
---|---|---|---|
1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 87,899 | I | See Footnote(1)(8) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Common Stock Warrants | 03/10/2004 | 03/15/2004(2) | Common Stock | 71,214 | 0.055 | I | See Footnotes(3)(8) |
Seried D Preferred Stock | 03/10/2004 | 03/15/2004(2) | Common Stock | 784,825 | 0.00(4) | I | See Footnotes(5)(8) |
Series E Preferred Stock | 03/10/2004 | 03/15/2004(2) | Common Stock | 130,802 | 0.00(6) | I | See Footnotes(7)(8) |
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
| ||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
Explanation of Responses: |
1. The shares are held as follows: 6,531 shares by MPM BioVentures II, L.P. ("BV II"), 59,174 shares by MPM BioVentures II-QP, L.P. ("BV QP"), 20,832 shares by MPM BioVentures GmbH & Co. Parallel Beteiligungs KG ("BV KG") and 1,362 shares by MPM Asset Management Investors 2000B LLC ("AM LLC"). |
2. The warrants shall expire and the preferred stock shall convert upon the closing of the Issuer's initial public offering. |
3. The warrant shares are held as follows: 5,291 shares by BV II, 47,942 shares by BV QP, 16,878 shares by BV KG and 1,103 shares by AM LLC. |
4. Each share of Series D Preferred Stock is convertible into 1 share of Common Stock upon the closing of Issuer's initial public offering. |
5. The shares are held as follows: 58,312 shares by BV II, 528,345 shares by BV QP, 186,004 shares by BV KG and 12,164 shares by AM LLC. |
6. Each share of Series E Preferred Stock is convertible into 1 share of Common Stock upon the closing of Issuer's initial public offering. |
7. The shares are held as follows: 9,718 shares by BV II, 88,057 shares by BV QP, 31,000 shares by BV KG and 2,027 shares by AM LLC. |
8. MPM Asset Management II LP ("AM II LP") and MPM Asset Management II LLC ("AM II LLC") are the direct and indirect general partners of BV II, BV QP and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Michael Steinmetz and Kurt Wheeler are members of AM II LLC and AM LLC. Each of the group disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein. |
Luke Evnin, manager of MPM Asset Management II, LLC, the general partner of MPM Management II LP, the general partner of MPM BioVentures II-QP, LP /s/ Luke Evnin | 03/10/2004 | |
Luke Evnin, manager of MPM Asset Management II, LLC, the general partner of MPM Management II LP, the general partner of MPM BioVentures II, LP /s/ Luke Evnin | 03/10/2004 | |
Luke Evnin, manager of MPM Asset Management II, LLC, the special limited partner of MPM Management II LP, the general partner of MPM BioVentures BmbH & Co. Parallel-Beteiligungs KG /s/ Luke Evnin | 03/10/2004 | |
Luke Evnin, manager of MPM Asset Management 2000B LLC /s/ Luke Evnin | 03/10/2004 | |
/s/ Ansbert Gadicke | 03/10/2004 | |
/s/ Luke Evnin | 03/10/2004 | |
/s/ Nicholas Galakatos | 03/10/2004 | |
/s/ Michael Steinmetz | 03/10/2004 | |
/s/ Kurt Wheeler | 03/10/2004 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |